The document describes the Preclinical Imaging Centre (PRIME) at Radboud University Nijmegen Medical Centre, which uses various imaging modalities like microSPECT, microPET, and multi-photon fluorescence microscopy to support drug development from preclinical testing through clinical trials. PRIME provides imaging services to evaluate new drugs and monitor treatment response in small animal models as well as humans.
Precision Oncology: Combining Orthotopic-PDX Models and MRI, Moving Research ...Scintica Instrumentation
Certis Oncology Solutions is a precision oncology and translational science company. It works directly with cancer patients and their oncologists to help determine the best therapies for individuals, and also partners with pharmaceutical companies to help develop the next generation of anticancer therapies. Certis’s approach to studying drug efficacy is rooted in orthotopic patient-derived xenograft (O-PDX) models. Because tumors are internal to the animal, they usually cannot be measured by calipers. Certis overcomes this challenge by using magnetic resonance imaging (MRI), employing the Aspect M3 Compact MRI to generate high-resolution 3D anatomical images to monitor anti-cancer therapies in real-time.
Topics that were discussed in this webinar :
- Overview of precision oncology and testing platforms
- Comparison on subcutaneous and orthotopic in vivo models
- Imaging modalities for pre-clinical in vivo studies
- Applications of MRI in precision oncology and preclinical in vivo pharmacology studies
Accelerating the Delivery of New Treatments for Children with Neuroblastoma 2...Scintica Instrumentation
Neuroblastoma is a tumour arising from anomalies in the development of the sympathic nervous system and still accounts for 13% of all cancer-related death in children due to resistant, relapsing and metastatic diseases. There is an urgent need for the development of new treatment against high-risk relapsed neuroblastoma.
Overview:
Here we will discuss the ICR Paediatric Mouse Hospital approach which integrates more advanced mouse modelling, such as the use of genetically-engineered mouse (GEM) models and patient-derived xenografts to accelerate the discovery and evaluation of novel therapeutic strategies and help shape the clinical trial pipeline priorities for children with high-risk relapsing/refractory neuroblastoma.
We will also highlight the pivotal role of MRI within the Mouse Hospital which includes:
Enhancing and accelerating preclinical trials
Quantitatively inform on tumour phenotype and tumour response to treatment to:
Develop in vivo models that emulate the clinical treatment resistant phenotype using chemotherapy-dose escalation protocol
Characterize tumour spatial heterogeneity and evolution over treatment and guide the pathological and molecular characterization of the resistant phenotype
Finally we will also discuss how the compact, cryogen-free and user-friendly Aspect Imaging M-Series has transformed our way of working within the mouse hospital by providing a shared and easily accessible resource for tumour screening (with minimal onboarding) .
A New Frontier of Precision Medicine: Using PET for Image-Guided Neurointerve...InsideScientific
Mice are by far the most frequently used animal for modeling disease and developing therapeutic strategies including neurointerventions. However, due to its anatomical and physiological barriers, the brain is a difficult target for delivery of therapeutic agents. Systemic administration is plagued with marginal brain accumulation and high risk of off-target side effects.
In this webinar sponsored by Scintica Instrumentation, Dr. Piotr Walczak, Dr. Mirosław Janowski and Dr. Wojciech Lesniak address this challenge and discuss why advanced imaging is essential to perform image-guided neurointerventions.
First, Dr. Janowski provides rationale as to how imaging can be used to better understand how therapeutic agents are delivered to the brain and subsequently cleared. Next, Dr. Walczak reviews methodological and technological advances for improving precision and reproducibility of brain targeting in mice based on MRI and two-photon microscopy. Finally, Dr. Lesniak presents recently-published results using ARGUS PET/CT to quantify intra-artrial delivery of antibodies, nanobodies and poly(amidoamine) dendrimers.
Key Topics Include:
- Overview of Pre-Clinical PET/CT imaging
- Examples from applications including oncology, neurology, cardiology and dynamic imaging
- An introduction to SuperArgus PET/CT and what makes it unique
To learn more, go to:
https://insidescientific.com/webinar/precision-medicine-using-pet-image-guided-neurointervention/
DESTINY – An Innovative Platform for Personalized Medicine from Doctors for D...IFAH
Arnfin Bergmann, CEO at NeuroTransData GmbH, on the topic of 'DESTINY – An Innovative Platform for Personalized Medicine from Doctors for Doctors & Patients' at IFAH held at Le Meridien, Dubai on 16th - 18th December, 2019.
Medical Imaging Seminar Company PresentationsSpace IDEAS Hub
Medical Imaging - Opportunities for Business Seminar
24/01/12
Short Company Presentations
14 companies took the opportunity to present a short sales pitch of their work and interests to the audience.
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at physicochemical characterisation new and novel approaches to understand the pharmacokinetics of complex drugs.
Juliana Maynard (MDC)
In Vivo Bioluminescent / Fluorescent Imagingachang07
The presentation is an introduction to using bioluminescent "reagents" to evaluate drug efficacy in tumor models. This presentation briefly highlights one of many research platforms available at Caliper Life Sciences\' Discovery Alliances\' In Vivo Division that performs contract research for the life science community.
Translational Applications of MiniPDX: An In Vivo Organoid Assay in New Drug R&DInsideScientific
Join Dr. Danyi Wen as she describes a novel drug efficacy test using Patient Derived Xenograft (PDX) samples to measure drug efficacy and identify therapeutic candidates in personalized oncology treatments.
LIDE’s novel MiniPDX is a 7-day, in vivo drug efficacy test for oncology therapeutics. It is the in vivo version of a 3D organoid assay and correlates with traditional PDX by 92%, and with clinical end point at 82%. These high correlations make MiniPDX an effective option to test targeted drugs, chemotherapies, angiogenesis drugs, and more, while demonstrating superior testing times and cost-effectiveness versus traditional PDX. In a clinical setting, MiniPDX, together with next-generation sequencing (NGS), is playing an emerging role in personalized oncology.
The process starts with a freshly prepared cell suspension from either a clinical sample or PDX (Patient Derived Xenograft) model. This sample is sealed into a mini capsule with 500 KD cut-off pores. Capsules are implanted into SCID mice subcutaneously, and a test compound is given systemically for 7 days. The efficacy of the test compound is then evaluated by measuring ATP of the cancer cells in the capsule.
The MiniPDX mouse trial can also be coupled with “K-Cell Omic” analysis (DNA, RNA, and Protein), presenting a powerful tool for the identification of drug candidates and the discovery of companion diagnostic markers.
Key Topics Include:
Understand how MiniPDX + Omics analysis empowers precision medicine
Pros and cons of functional diagnosis assays (CR, Organoid, MiniPDX, PDX)
How to leverage MiniPDX + Omics for the identification of drug candidates
Role of K Cell RNAseq + FGI (Functional Genomic Imaging)
LIDE’s PMed Trial database for AI aided drug discovery
Advances in radiation oncology:Cancer careAjeet Gandhi
Radiation therapy has tremendous capacity for cancer cure. Advancement in last few decades have further enhanced its outcome. Global access would save many lives
Precision Oncology: Combining Orthotopic-PDX Models and MRI, Moving Research ...Scintica Instrumentation
Certis Oncology Solutions is a precision oncology and translational science company. It works directly with cancer patients and their oncologists to help determine the best therapies for individuals, and also partners with pharmaceutical companies to help develop the next generation of anticancer therapies. Certis’s approach to studying drug efficacy is rooted in orthotopic patient-derived xenograft (O-PDX) models. Because tumors are internal to the animal, they usually cannot be measured by calipers. Certis overcomes this challenge by using magnetic resonance imaging (MRI), employing the Aspect M3 Compact MRI to generate high-resolution 3D anatomical images to monitor anti-cancer therapies in real-time.
Topics that were discussed in this webinar :
- Overview of precision oncology and testing platforms
- Comparison on subcutaneous and orthotopic in vivo models
- Imaging modalities for pre-clinical in vivo studies
- Applications of MRI in precision oncology and preclinical in vivo pharmacology studies
Accelerating the Delivery of New Treatments for Children with Neuroblastoma 2...Scintica Instrumentation
Neuroblastoma is a tumour arising from anomalies in the development of the sympathic nervous system and still accounts for 13% of all cancer-related death in children due to resistant, relapsing and metastatic diseases. There is an urgent need for the development of new treatment against high-risk relapsed neuroblastoma.
Overview:
Here we will discuss the ICR Paediatric Mouse Hospital approach which integrates more advanced mouse modelling, such as the use of genetically-engineered mouse (GEM) models and patient-derived xenografts to accelerate the discovery and evaluation of novel therapeutic strategies and help shape the clinical trial pipeline priorities for children with high-risk relapsing/refractory neuroblastoma.
We will also highlight the pivotal role of MRI within the Mouse Hospital which includes:
Enhancing and accelerating preclinical trials
Quantitatively inform on tumour phenotype and tumour response to treatment to:
Develop in vivo models that emulate the clinical treatment resistant phenotype using chemotherapy-dose escalation protocol
Characterize tumour spatial heterogeneity and evolution over treatment and guide the pathological and molecular characterization of the resistant phenotype
Finally we will also discuss how the compact, cryogen-free and user-friendly Aspect Imaging M-Series has transformed our way of working within the mouse hospital by providing a shared and easily accessible resource for tumour screening (with minimal onboarding) .
A New Frontier of Precision Medicine: Using PET for Image-Guided Neurointerve...InsideScientific
Mice are by far the most frequently used animal for modeling disease and developing therapeutic strategies including neurointerventions. However, due to its anatomical and physiological barriers, the brain is a difficult target for delivery of therapeutic agents. Systemic administration is plagued with marginal brain accumulation and high risk of off-target side effects.
In this webinar sponsored by Scintica Instrumentation, Dr. Piotr Walczak, Dr. Mirosław Janowski and Dr. Wojciech Lesniak address this challenge and discuss why advanced imaging is essential to perform image-guided neurointerventions.
First, Dr. Janowski provides rationale as to how imaging can be used to better understand how therapeutic agents are delivered to the brain and subsequently cleared. Next, Dr. Walczak reviews methodological and technological advances for improving precision and reproducibility of brain targeting in mice based on MRI and two-photon microscopy. Finally, Dr. Lesniak presents recently-published results using ARGUS PET/CT to quantify intra-artrial delivery of antibodies, nanobodies and poly(amidoamine) dendrimers.
Key Topics Include:
- Overview of Pre-Clinical PET/CT imaging
- Examples from applications including oncology, neurology, cardiology and dynamic imaging
- An introduction to SuperArgus PET/CT and what makes it unique
To learn more, go to:
https://insidescientific.com/webinar/precision-medicine-using-pet-image-guided-neurointervention/
DESTINY – An Innovative Platform for Personalized Medicine from Doctors for D...IFAH
Arnfin Bergmann, CEO at NeuroTransData GmbH, on the topic of 'DESTINY – An Innovative Platform for Personalized Medicine from Doctors for Doctors & Patients' at IFAH held at Le Meridien, Dubai on 16th - 18th December, 2019.
Medical Imaging Seminar Company PresentationsSpace IDEAS Hub
Medical Imaging - Opportunities for Business Seminar
24/01/12
Short Company Presentations
14 companies took the opportunity to present a short sales pitch of their work and interests to the audience.
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at physicochemical characterisation new and novel approaches to understand the pharmacokinetics of complex drugs.
Juliana Maynard (MDC)
In Vivo Bioluminescent / Fluorescent Imagingachang07
The presentation is an introduction to using bioluminescent "reagents" to evaluate drug efficacy in tumor models. This presentation briefly highlights one of many research platforms available at Caliper Life Sciences\' Discovery Alliances\' In Vivo Division that performs contract research for the life science community.
Translational Applications of MiniPDX: An In Vivo Organoid Assay in New Drug R&DInsideScientific
Join Dr. Danyi Wen as she describes a novel drug efficacy test using Patient Derived Xenograft (PDX) samples to measure drug efficacy and identify therapeutic candidates in personalized oncology treatments.
LIDE’s novel MiniPDX is a 7-day, in vivo drug efficacy test for oncology therapeutics. It is the in vivo version of a 3D organoid assay and correlates with traditional PDX by 92%, and with clinical end point at 82%. These high correlations make MiniPDX an effective option to test targeted drugs, chemotherapies, angiogenesis drugs, and more, while demonstrating superior testing times and cost-effectiveness versus traditional PDX. In a clinical setting, MiniPDX, together with next-generation sequencing (NGS), is playing an emerging role in personalized oncology.
The process starts with a freshly prepared cell suspension from either a clinical sample or PDX (Patient Derived Xenograft) model. This sample is sealed into a mini capsule with 500 KD cut-off pores. Capsules are implanted into SCID mice subcutaneously, and a test compound is given systemically for 7 days. The efficacy of the test compound is then evaluated by measuring ATP of the cancer cells in the capsule.
The MiniPDX mouse trial can also be coupled with “K-Cell Omic” analysis (DNA, RNA, and Protein), presenting a powerful tool for the identification of drug candidates and the discovery of companion diagnostic markers.
Key Topics Include:
Understand how MiniPDX + Omics analysis empowers precision medicine
Pros and cons of functional diagnosis assays (CR, Organoid, MiniPDX, PDX)
How to leverage MiniPDX + Omics for the identification of drug candidates
Role of K Cell RNAseq + FGI (Functional Genomic Imaging)
LIDE’s PMed Trial database for AI aided drug discovery
Advances in radiation oncology:Cancer careAjeet Gandhi
Radiation therapy has tremendous capacity for cancer cure. Advancement in last few decades have further enhanced its outcome. Global access would save many lives
2. RTM: Radboud Translational Medicine
from molecule to man
Discovery Screening preclinical testing Clinical trials
Radboud University Nijmegen Medical Centre, The Netherlands
3. RTM: Radboud Translational Medicine
from molecule to man
Discovery Screening preclinical testing Clinical trials
Radboud University Nijmegen Medical Centre, The Netherlands
6. From human imaging to small animal imaging
Mouse Human
Uptake of 123I-IBF
by D2 receptors
Neurology Dopamine w/ 99mTc-TRODAT
99m
Tc-MIBI
Cardiovascular Stress 99mTc-MIBI
[99mTc] Minigastrin
Oncology Renal Cell Carcinoma
*functional imaging
15. FDG-PET: functional imaging
Monitor response to treatment
Pre treatment
4 weeks after
start of treatment
24 weeks after
start of treatment
Pre treatment
Dept. Nuclear Medicine, Radboud University Nijmegen Medical Centre
16. FDG-PET: functional imaging
Monitor response to treatment
Pre treatment
4 weeks after
start of treatment
24 weeks after
start of treatment
Pre treatment 1 week after start of
imatinib treatment
Dept. Nuclear Medicine, Radboud University Nijmegen Medical Centre
17. FDG-PET: functional imaging
Monitor response to treatment
Pre treatment
4 weeks after
start of treatment
24 weeks after
start of treatment
Pre treatment 1 week after start of
imatinib treatment
Dept. Nuclear Medicine, Radboud University Nijmegen Medical Centre
18. microPET/CT scanner
Radboud University Nijmegen Medical Centre, The Netherlands
19. Monitor the therapeutic effect
of a new anti-cancer drug
- 1 day
Radboud University Nijmegen Medical Center, The Netherlands
20. Monitor the therapeutic effect
of a new anti-cancer drug
- 1 day 1 day
Radboud University Nijmegen Medical Center, The Netherlands
21. Monitor the therapeutic effect
of a new anti-cancer drug
- 1 day 1 day 3 days
Radboud University Nijmegen Medical Center, The Netherlands
22. Monitor the therapeutic effect
of a new anti-cancer drug
- 1 day 1 day 3 days 7 days
Radboud University Nijmegen Medical Center, The Netherlands
26. microSPECT imaging
Radboud University Nijmegen Medical Centre, The Netherlands
27. Imaging transplated islets of Langerhans
Diabetes type 1: autoimmune destruction of insulin producing beta cells
Islet transplantation is a promising treatment for patients with type1 diabetes
AIM: Non-invasive in vivo determination of beta cell mass after islet transplantation.
In-111-DTPA-
Exendin
islets
Radboud University Nijmegen Medical Centre, The Netherlands
38. Drug development Research
Hoffmann La Roche
Novartis
Sanofi
Fuji Biotechnology
Future Chemistry
Immunomedics Inc.
Synaffix
Wilex
Milabs
Radboud University Nijmegen Medical Centre, The Netherlands
Editor's Notes
At the moment more than 180 million people worldwide suffer from diabetes and an increase of the incidence of diabetes is expected.
MIP maximum intensity projection VRT volume rendering technique